Progressive Supranuclear Palsy - A Pipeline Analysis Report

Overview of the drug development pipeline for progressive supranuclear palsy

Progressive supranuclear palsy (PSP) is a rare and progressive neurodegenerative disease, which is commonly known as Steele-Richardson-Olszewski syndrome. This condition is caused by the gradual damage of brain cells and the patients suffering from this condition undergo changes in personality, stiffness of muscles, dizziness, arthralgia, challenges with vision, speech, and facial movements, depression, and lack of interest. The prevalence of PSP is high among people above the age of 60. As a result, the growth of the global geriatric population will drive the demand for PSP treatments. Technavio’s market research analysts have predicted that with the introduction of medication, physiotherapy, speech therapy, and feeding tubes as some of the most promising investigational approaches to treat progressive supranuclear palsy, the global progressive supranuclear palsy market will witness growth in the forthcoming years.

According to progressive supranuclear palsy market overview, most of the drug development molecules in the pipeline are under the phase I and phase II development stages. For instance, sponsors such as Asceneuron developed ASN120290 and AbbVie developed ABBV-8E12, which are under phase I and phase II development stages respectively. Our market research analysts have also identified that a small amount of drug molecules that are being developed comes under the phase II/III development stage. The pipeline landscape in the pipeline analysis report mentions the percentage of drug development molecules that are under the pre-clinical stage.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of progressive supranuclear palsy. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.